Acurx Pharmaceuticals (ACXP) to Release Quarterly Earnings on Tuesday

Acurx Pharmaceuticals (NASDAQ:ACXPGet Free Report) is expected to be announcing its earnings results before the market opens on Tuesday, March 18th. Analysts expect the company to announce earnings of ($0.18) per share for the quarter. Investors that wish to register for the company’s conference call can do so using this link.

Acurx Pharmaceuticals Stock Performance

NASDAQ:ACXP opened at $0.46 on Monday. The firm has a market capitalization of $9.04 million, a PE ratio of -0.42 and a beta of -1.71. The stock has a 50-day simple moving average of $0.73 and a two-hundred day simple moving average of $1.29. Acurx Pharmaceuticals has a 52-week low of $0.43 and a 52-week high of $3.33.

Insider Transactions at Acurx Pharmaceuticals

In other news, CEO David P. Luci purchased 49,261 shares of the company’s stock in a transaction that occurred on Monday, January 6th. The stock was bought at an average cost of $1.01 per share, with a total value of $49,753.61. Following the completion of the purchase, the chief executive officer now owns 1,097,458 shares in the company, valued at approximately $1,108,432.58. This represents a 4.70 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through this hyperlink. Corporate insiders own 29.60% of the company’s stock.

Analyst Ratings Changes

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $12.00 price objective on shares of Acurx Pharmaceuticals in a research note on Friday, January 10th.

Check Out Our Latest Stock Analysis on ACXP

About Acurx Pharmaceuticals

(Get Free Report)

Acurx Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections.

See Also

Earnings History for Acurx Pharmaceuticals (NASDAQ:ACXP)

Receive News & Ratings for Acurx Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acurx Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.